Anavo Therapeutics
Leiden
About Anavo Therapeutics
Anavo Therapeutics is the first company to systematically drug phosphatases, a rich target space previously considered undruggable for decades. We have attracted world-leading scientific expertise in phosphatase-driven disease biology and drug discovery to unlock the full potential of phosphatase-targeted allosteric modulators. In oncology, Anavo is developing multiple first-in-class therapeutic programs and will build on partnerships around its platform to establish a rich pipeline across several indications
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $33.4M
- Funding stage: Seed
- Last round: Seed (May 2023)
- Website: anavotx.com
Industries & Categories
Biotechnology, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/anavo-therapeutics-51703 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.